BCL2 and acute lymphoblastic leukemia: Effective drug combinations were identified for high-risk BCP ALL including Ph-like ALL (BCL-2 and MCL-1 inhibitors; TK inhibitors dasatinib and ponatinib) [131,132], T-ALL and ETP-ALL (ruxolitinib and dexamethasone; dasatinib; and venetoclax and bortezomib) [133,134].